ESSA Shareholders Give Green Light to XenoTherapeutics Acquisition

Written by Emily J. Thompson, Senior Investment Analyst

EPIX%

Source: Newsfilter

Updated: Oct 06 2025

0mins

Source: Newsfilter

Acquisition Approval: ESSA Pharma Inc. has received overwhelming approval from its Securityholders for the acquisition by XenoTherapeutics Inc., with over 99% of votes in favor during a special meeting.
Next Steps: The transaction is pending approval from the Supreme Court of British Columbia, with a court hearing scheduled for October 7, 2025, and completion expected around October 9, 2025.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

ESSA Shareholders Give Green Light to XenoTherapeutics Acquisition

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Organon (OGN) Receives FDA Approval for Nexplanon Label Expansion to 5 Years

VanEck Increases Strategy Holdings, Responds to NYT Report

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch